THE COURSE OF CHRONIC HEART FAILURE IN PERSONS WITH POST-INFARCTION CARDIOSCLEROSIS AND TYPE 2 DIABETES MELLITUS AND OBESITY ACCORDING TO A NUMBER OF METABOLIC AND HORMONAL INDICATORS

Authors

DOI:

https://doi.org/10.21856/j-PEP.2022.2.02

Keywords:

chronic heart failure, obesity, postinfarction cardiosclerosis, type 2 diabetes, biomarkers of inflammation

Abstract

The aim of the study is to investigate the effect of lipid metabolism, biomarkers of fractalkin and clusterin inflammation on the development and progression of chronic heart failure in patients with post-infarction cardiosclerosis, type 2 diabetes and obesity. A retrospective analysis of a comprehensive examination of 67 patients with postinfarction cardiosclerosis with concomitant type 2 diabetes and obesity. All patients were divided into 3 groups depending on the functional class (FC) of CHF: 1 group (n = 22) - patients with CHF II FC; Group 2 (n = 23) - patients with CHF III FC; Group 3 (n = 22) - patients with CHF IV FC. All patients were examined clinically, they were instrumental, biochemical and hormonal examination. With the progression of CHF from FC II to FC III there is a deterioration of lipid metabolism: a significant increase in cholesterol levels by 5.5%, TG - by 15.7%, LDL cholesterol - by 74.4%, VLDL cholesterol - by 15 , 9%, reduction of HDL cholesterol - by 27.6% (p <0,05). An analysis of the fractal equation showing that ailing on CHF is advised by FC; rіven clusterin –decrease. Classical changes in patients with postinfarction cardiosclerosis with CHF and concomitant type 2 diabetes mellitus and obesity , which are the formation of atherogenic lipid metabolism disorders associated with body weight, as well as changes in the latest indicators such as fractalkin and clusterin , indicating the role of these molecules in the progression of CHF.

 

References

Alpert CM, Smith MA, Hummel SL, et al. Heart Fail Rev 2017;22(1): 25-39.

Voronkova LG. Rekomendaczii Assocziaczii kardiologov Ukrainy` po diagnostike i lecheniyu khronicheskoj serdechnoj nedostaatochnosti. Ukr J Cardiol 2018;3: 11-76.

Khan H, Anker SD, Januzzi JL, et al. J Card Fail 2019;25(2): 78-86.

Virani SS, Alonso A, AparicioHJ, et al. Circulation 2021;143(8): e254-e743. https://doi.org/10.1161/CIR

Aleksandrova EB. Cardiology 2013;53(7): 40-44.

Ofstad AP, Atar D, Gullestad L, et al. Heart Fail Rev 2018;23(3): 303-323.

Dauriz M, Mantovani A, Bonapace S, et al. Diabetes Care 2017;40: 1597-1605.

Neeland IJ, Gupta S, Ayers CR, et al. Circ Cardiovasc Imaging 2013;6(5): 800-807.

Aune D, Sen A, Norat T, et al. Circulation 2016;133(7): 639-649.

Daimon M, Oizumi T, Karasawa S, et al. Metabolism 2011;60(6): 815-22. https://doi.org/10.1016/j.metabol.2010.07.033.

Ray KK, Del Prato S, Müller-Wieland D, et al. Cardiovasc Diabetol 2019;18(1): 149. https://doi.org/10.1186/s12933-019-0951-9.

Park S, Mathis KW, Lee IK. Rev Endocr Metab Disord 2014;15(1): 45-53. https://doi.org/10.1007/s11154-013-9275-3.

Njerve IU, Byrkjeland R, Arnesen H, et al. Diab Metab Syndr Obes 2016;9: 55-62. https://doi.org/10.2147/DMSO.S96299.

Ruze A, Zhao Y, Li H, et al. Blood Coagul Fibrinolysis 2018;29(4): 361-368. https://doi.org/10.1097/MBC.0000000000000701.

Hirono K, Imaizumi T, Aizawa T, et al. Mod Rheumatol 2020;30(6): 1074-1081. https://doi.org/10.1080/14397595.2019.1682768.

Jones BA, Beamer M, Ahmed S. Mol Interv.2010;10(5): 263-270. https://doi.org/10.1124/mi.10.5.3.

Irace C. Hypertension 2005;45: 597-601.

Seravalle G, Grassi G. High Blood Press Cardiovasc Prev 2016;23: 175-179. https://doi.org/10.1007/s40292-016-0137-4.

Forrester SJ, Booz GW, Sigmund CD, et al. Physiol Rev 2018;98(3): 1627-1738. https://doi.org/10.1152/physrev.00038.

LaRocca TJ, Schwarzkopf M, Altman P, et al. J Cardiovasc Pharmacol 2010;56: 548-559.

Pyo RT, Sui J, Dhume A, et al. J Mol Cell Cardinol 2006;41: 834-844.

Amosova EN, Mjasnikov GV, Sidorova LL. Ukr Terapevt Zhurn 2007;2: 17-25.

Bilovol OM, Shkol'nyk VV, Andrejeva AO. Ukr Terapevt Zhurn 2011;3: 34-37.

Horr S, Nissen S. Clin Endocrinol Metab 2016;30(3): 445-454. https://doi.org/10.1016/j.beem.2016.06.001.

Downloads

Published

2022-06-09

How to Cite

Dunaieva, I., Bilovol, O., & Knyazkova, I. (2022). THE COURSE OF CHRONIC HEART FAILURE IN PERSONS WITH POST-INFARCTION CARDIOSCLEROSIS AND TYPE 2 DIABETES MELLITUS AND OBESITY ACCORDING TO A NUMBER OF METABOLIC AND HORMONAL INDICATORS. Problems of Endocrine Pathology, 79(2), 14-18. https://doi.org/10.21856/j-PEP.2022.2.02

Issue

Section

CLINICAL ENDOCRINOLOGY